R heumatoid arthritis (RA)
4 is a chronic inflammatory autoimmune disease that affects ϳ1% of the population. Recent studies demonstrate a significant improvement in clinical symptoms of disease in patients treated with rituximab, an anti-CD20 mAb that depletes pre-B cells and mature B cells but not plasma cells (1) (2) (3) . This finding indicates that B cells significantly contribute to the pathogenesis of RA. Autoantibodies produced by B cells may be directly pathogenic in RA or may indirectly contribute to disease through the formation of immune complexes and the activation of the complement cascade and Fc␥ receptors (4, 5) . However, the pathogenic consequences of autoreactive B cell activation are not limited to Ab production. B cells have the capacity to promote T cell activation through their ability to process and present Ag 10 3 -to 10 4 -fold more effectively than other APCs, suggesting that B cells may be important for the presentation of autoantigens that are at low concentrations (6) . The role of B cells as APCs has been extensively studied (6 -12) . In a murine model of RA, proteoglycan (PG)-induced arthritis (PGIA), we have demonstrated that the activation of autoreactive T cells is dependent on the specific recognition of PG by the BCR. In the absence of BCR recognition of PG, the development of arthritis is inhibited (13) . This interaction between B and T cells is direct and does not involve the presentation of Ag by immune complexes taken up by macrophages or dendritic cells (DCs), because PG-specific T cell activation occurs in mice deficient in circulating Ig (13) .
Activation of naive T cells requires signaling through the Agspecific TCR and costimulatory molecules. The best-characterized costimulatory pathway is CD28 on T cells and CD80/CD86 on APCs (14) . Ab blocking studies and studies in CD28-and CD80/ CD86-deficient mice support the importance of this pathway in CD4 ϩ T cell activation. In autoimmune disease models where T cells are critical, combined blockade of CD80 and CD86 inhibits the development of disease (15) (16) (17) (18) (19) (20) .
Mouse naive B cells express low levels of costimulatory molecules that are up-regulated upon LPS, BCR, anti-CD40, or IL-4 stimulation (16, (21) (22) (23) (24) (25) (26) . Once the B cells are activated and express CD80/86, they have the potential to receive signals from T cells or reciprocally signal T cell activation. A recent study demonstrated that CD80/86 costimulatory-dependent signaling on B cells is not essential for Ab production (27) . However, because CD28 ϩ T cells interact with CD80/86 on several different APCs it has been difficult to determine in vivo whether selective expression of CD80/86 on B cells verses other APCs is essential for T cell activation. In PGIA, we have shown that engagement of the BCR with PG induces B cell proliferation and up-regulation of CD86 expression, suggesting that B cell costimulatory molecule expression may be important for T cell activation. The precise requirement for B cell CD80/86 signaling to T cells has not been established in autoimmunity under physiological in vivo conditions.
The experiments described in this report test whether B cellspecific expression of CD80/86 is required for the development of PGIA. We generated mixed bone marrow (BM) chimeras in which only the B cells were defective in CD80/86 expression. Our results demonstrate that a deficiency in B cell expression of CD80/86 prevented the development of PGIA despite normal production of PG-specific autoantibodies. However, autoreactive T cells from PG-immunized CD80/CD86
Ϫ/Ϫ B cell chimeric mice were less effective at transferring disease into SCID recipients. Thus, B cell expression of the CD80/CD86 costimulatory molecules is critical for the generation of autoimmunity by regulating autoreactive T cell activation.
Materials and Methods

Mice
Female BALB/c and SCID on BALB/c background (NCrC.B-17-scid/scid) mice were purchased from the National Caner Institute (Frederick, MD). B cell-deficient (B cell Ϫ/Ϫ ) mice contain homozygous deletion of the joining H chain region Ig DNA (J H D) due to a neo insertion in the J H locus and are incapable of developing mature B cells (28) . B cell Ϫ/Ϫ mice were generously provided by Dr. M. Shlomchik (Yale University, New Haven, CT). CD80/CD86-deficient (CD80/86 Ϫ/Ϫ ) mice were generously provided by Dr. A. Sharpe (Harvard University, Boston, MA) (29) .
Induction and assessment of arthritis
Human cartilage was obtained after joint replacement surgery and PG (aggrecan) was subsequently isolated as described (30) . Female mice, Ͼ3 mo of age, were immunized i.p. with 150 g of human PG measured as protein, emulsified in dimethyldioctadecylammonium bromide (DDA) (Sigma-Aldrich) as previously described (13) , and boosted with 100 g of PG/DDA at 3 and 6 wk. Mice were monitored for arthritis and scored in a blinded manner. Paws were scored for arthritis on a scale from 1 to 4: 0, normal; 1, mild swelling affecting several digits or mild swelling of the paw; 2, moderate erythema and swelling of the paw; 3, more intense erythema, swelling and redness affecting a greater proportion of the paw; 4, severe erythema, swelling and redness affecting the entire paw. Each animal received a cumulative score ranging from 0 to 16, based on individual paw scores of 0 to 4.
BM chimeras
Female BALB/c mice (8 -10 wks of age) were given acidified water one week before irradiation and BM reconstitution. Mice were switched to trimethoprim-sulfamethoxazole-treated water on the day of cell transfer; this was continued for 1 mo. Mice were lethally irradiated with two separate doses of 450 rad 3 h apart using a 137 Cs source. Following the second irradiation dose, mice were reconstituted with BM cells that were obtained from intact femurs of donor mice. BM were depleted of RBCs with Tris-NH 4 Cl buffer and then depleted or not depleted of Thy1.2 (CD90)-expressing T cells with anti-CD90-microbeads using an autoMACS system (Miltenyi Biotec). In several experiments, no difference was observed between reconstitutions of recipient mice with T cell-depleted or nondepleted BM cells. 
Adoptive transfer of PGIA into SCID mice
T cells from chimeras were tested for their ability to transfer arthritis into SCID recipients. Nylon wool-purified T cells (1 ϫ 10 7 ) from PG-immunized chimeras were mixed with T cell-depleted (Thy1.2 (CD90) microbeads (Miltenyi-Biotec)) spleen cells (2 ϫ 10 7 ) from WT arthritic mice. Cells and 100 g of PG were injected i.p. into female SCID mice. SCID mice were examined for arthritis onset and severity every 3 days after cell transfer.
Detection of anti-PG Ab by ELISA
Mice immunized with human PG were bled from the orbital plexus and serum was obtained and examined for Abs against mouse PG and human PG by ELISA. Enzyme immunoassay tissue culture 96-well "half area" plates (Costar; Corning) were coated overnight at 4°C with 0.5 g of chondroitinase avidin-biotin-peroxidase (ABC)-digested human PG or 0.75 g of native mouse PG in carbonate buffer. Serum was serially diluted in buffer (PBS with 0.5% Tween 20) . Serum dilutions of 1/50 and 1/100 were used to determine the titer of IgG1 Abs against mouse PG. Dilutions of 1/2,500, 1/12,500, and 1/62,500 were used to determine the titer of IgG1 Abs against human PG. Samples were run in duplicate. Abs were detected with HRP-labeled rabbit anti-mouse IgG1 (Zymed Laboratories), which was then detected with the substrate o-phenylenediamine. Colorimetric change in each sample was measured with a spectrophotometer at 490 nm, and the relative concentration was determined from a standard curve of known concentrations of unlabeled murine IgG1 Ab (Southern Biotechnology). Data represent the mean Ϯ SEM of Abs from 4 -6 individual mice.
Assessment of T cell activation
Nylon wool-purified T cells (2.5 ϫ 10 5 cells/well) from peritoneal exudates (pooled from 4 -6 mice) of PG-immunized or CD4 ϩ T cells from spleen of SCID (adoptive transfer) or PG-immunized mice were purified by negative selection using microbeads (Miltenyi-Biotec) and stimulated with PG (10 g/ml) and irradiated (2500 rad) spleen cells from naive WT mice. In other experiments as indicated in figure legends, CD4
ϩ T cells from PG-immunized mice were stimulated with irradiated purified B cells (Miltenyi-Biotec), either naive or activated overnight with 10 g/ml LPS. Cells were cultured in quadruplicate in 96-well Falcon plates (Fisher Scientific) in RPMI 1640 medium containing 10% FCS, 100 g/ml penicillin, 100 g/ml streptomycin, and 2 mM L-glutamine. Cultures were pulsed on day 4 with [ 3 H]thymidine overnight and examined for proliferation. CD4 ϩ T cells cytokines (IFN-␥, IL-4, and IL-17) were measured from the spleens of SCID mice stimulated with PG (10 g/ml) and irradiated (2500 rad) spleen cells from naive WT mice by ELISA (BD Biosciences). 
Statistical analysis
The nonparametric Mann-Whitney U test was used to compare data for statistical significance. Significance is based on p Ͻ 0.05.
Results
CD80/CD86-deficient mice (CD80/86 Ϫ/Ϫ ) are resistant to PGIA
The costimulatory molecules CD80 and CD86 are essential for T cell-dependent immune responses, and because PGIA is a T celland B cell-mediated autoimmune disease we anticipated that CD80/86-deficient (CD80/86 Ϫ/Ϫ ) mice would be resistant to PGIA. WT and CD80/86 Ϫ/Ϫ mice were immunized with PG and the development of disease was monitored over time. The WT mice developed severe inflammatory arthritis with 100% incidence of disease, whereas the CD80/86 Ϫ/Ϫ mice failed to develop arthritis (Fig. 1, A and B) . Thus, the expression of CD80/86 costimulatory molecules by APCs is required for the induction of PGIA.
It has been previously shown that both T cell and B cell responses are defective in CD80/86 Ϫ/Ϫ mice. To determine whether resistance to PGIA was due to reduced B and T cell responses, we examined PG-specific Ab production and PG-specific T cell proliferation. Both PG-specific T cell and B cell responses were decreased in CD80/86 Ϫ/Ϫ mice (Fig. 1, C and D) . These data confirm previous reports on the requirement for a CD80/86-CD28 pathway in the induction of arthritis and the generation of T and B cell responses (31) (32) (33) .
Creation of mice with a CD80/86 deficiency restricted to the B cell compartment
Although complete deficiency of CD80 and CD86 prevents arthritis and accompanying T cell-dependent responses, it is unclear whether the expression of these costimulatory molecules on B cells is essential for the induction of PGIA. We have previously shown that Ag-specific B cells are important as APCs for the activation of autoreactive T cells and that the expression of CD86 is up-regulated on Ag-specific B cells after priming with PG in vivo (13) . To determine whether B cell expression of CD80/86 is required for PGIA, we created mice in which CD80/86-deficient B cells coexist with other APC populations that express CD80/86. Lethally irradiated WT recipient mice were reconstituted with a mixture of BM from B cell-deficient (B cell Ϫ/Ϫ ) and CD80/86 Ϫ/Ϫ mice (B cell: CD80/86 Ϫ/Ϫ ). In these chimeric mice the APC compartment will be derived partially from the B cell Ϫ/Ϫ BM and thus give rise to CD80/86-positive non-B cell APCs, whereas the B cells will arise from CD80/86-negative BM. Positive control chimeras were a mixture of BM from B cell Ϫ/Ϫ and WT mice (B cell:CD80/86 ϩ/ϩ ), and negative control chimeras were BM from either B cell Ϫ/Ϫ or CD80/86 Ϫ/Ϫ mice injected into lethally irradiated WT recipient mice. Chimeras were analyzed for CD86 expression by flow cytometry on B220 ϩ and B220 Ϫ cells in peripheral blood 3 mo after reconstitution (Fig. 2) . The percentage of B220 ϩ B cells in B cell: CD80/86 Ϫ/Ϫ chimeras was similar to that of positive control B cell:CD80/86 ϩ/ϩ and negative control CD80/86 Ϫ/Ϫ chimeras but, as expected, substantially higher than that of B cell Ϫ/Ϫ chimeras ( Fig. 2A) (Fig. 2D ). These data suggest that CD86 expression might confer a survival advantage on the non-B cell APC.
Development of PGIA requires B cell CD80/86 expression
To determine whether the expression of CD80/86 on B cells is required for the development of PGIA, nonchimeric WT and chimeric groups were immunized with PG and evaluated for arthritis incidence and severity (Fig. 3) . B cell:CD80/86 ϩ/ϩ chimeras developed arthritis with 100% incidence and similar severity as that of nonchimeric WT mice (Fig. 3, A and B) . B cell:CD80/86 Ϫ/Ϫ chimeras with a specific deletion of CD80/86 expression on B cells and not other APCs were resistant to arthritis as were chimeras with either no B cells (B cell Ϫ/Ϫ ) or a complete deficiency in CD80/86 expression (CD80/86 Ϫ/Ϫ ). Similar results were obtained in a second experiment (Fig. 3, C and D) . These data demonstrate that expression of CD80/86 on B cells is required for the development of PGIA.
To ϩ/ϩ chimeras was characteristic of acute arthritis. Mononuclear and polymorphonuclear cell infiltration was abundant in the tissues and joint spaces. There was edema of the synovial and periarticular tissues accompanied by synovial hyperplasia. Cartilage erosion and disintegrating chondrocytes were also seen in the remaining layer of the articular surface (Fig. 4A) . Conversely, cellular infiltrates and histopathological signs of arthritis were completely absent in B cell:CD80/86
, and CD80/86 Ϫ/Ϫ chimeras (Figs. 4, B-D) . In these mice, the lack of paw erythema and swelling correlated with the absence of cellular infiltrate and joint destruction (Figs. 3D and 4, B-D) . 
B cell expression of CD80/86 is not required for Ab production
In PGIA, Abs specific for PG are an essential component in the pathogenesis of disease. Hence, it is possible that the expression of CD80/86 on B cells is required for the development of PG-specific Abs. Nonchimeric WT and chimeras immunized with PG were assessed for PG-specific Abs (Fig. 5 ). Chimeric B cell:CD80/ 86 ϩ/ϩ and B cell:CD80/86 Ϫ/Ϫ mice produced PG-specific IgG1 Abs equivalent to those of PG-immunized nonchimeric WT mice, whereas PG-specific Abs in B cell Ϫ/Ϫ and CD80/86 Ϫ/Ϫ chimeras were almost undetectable. Thus, the failure of B cell:CD80/86 Ϫ/Ϫ chimeras to develop arthritis is not due to a lack of PG-specific Abs. These studies also confirm a previous report demonstrating that CD80/86 expression on B cells is not required for Ab production (18) . However, mice that completely lack CD80/86 expression on all APCs fail to generate PG-specific Abs, indicating that these costimulatory molecules must be expressed in vivo by non-B cell APC populations to generate a humoral immune response.
B cell expression of CD80/86 critically regulates autoreactive T cell activation
To determine whether expression of CD80/86 by B cells is necessary for autoreactive T cell activation, we tested whether primed T cells in the chimeras were able to transfer disease. To do this, we transferred purified T cells from PG-immunized B cell:CD80/ 86 ϩ/ϩ , B cell:CD80/86 Ϫ/Ϫ , CD80/86 Ϫ/Ϫ , or B cell Ϫ/Ϫ chimeras and B cells and APCs (T cell-depleted spleen) from WT arthritic mice into SCID recipients. SCID mice that received T cells from B cell:CD80/86 ϩ/ϩ chimeras and B cells and APCs from arthritic WT mice developed severe arthritis (Figs. 6, A and B) . T cells from the B cell:CD80/86 ϩ/ϩ chimeras were significantly more effective at transferring arthritis than T cells from B cell:CD80/86 Ϫ/Ϫ , CD80/86 Ϫ/Ϫ , or B cell Ϫ/Ϫ chimeras. Arthritis was delayed by several weeks in SCID mice that received T cells from B cell:CD80/ 86 Ϫ/Ϫ , CD80/86 Ϫ/Ϫ , or B cell Ϫ/Ϫ chimeras. Although 100% of SCID mice that received T cells from B cell:CD80/86 Ϫ/Ϫ eventually developed arthritis, the degree of inflammation was significantly reduced in comparison to SCID mice receiving T cells from B cell:CD80/86 ϩ/ϩ chimeras. These data demonstrate that B cell expression of CD80/86 is necessary to adequately activate T cells to transfer arthritis.
To further evaluate T cell activation, T cells were recovered from spleens of SCID recipient mice and reactivated in vitro with PG (Fig. 6C) . T cells purified from SCID recipients were stimulated with PG in the presence of irradiated naive WT spleen cells. Proliferation was substantially higher from B cell:CD80/86 ϩ/ϩ chimera T cells than from either B cell:CD80/86 Ϫ/Ϫ , CD80/86 Ϫ/Ϫ , or B cell Ϫ/Ϫ chimera T cells. To determine whether CD80/86 deficiency on B cells skewed T cell cytokine subsets, we evaluated T cell cytokine production. IFN-␥, IL-4, and IL-17 were not significantly different between the experimental groups. Both IL-4 and IL-17 production were low whereas IFN-␥ production was elevated but not decreased in comparison (Fig. 6D) . These data provide evidence that B cell expression of CD80/86 is important for the in vivo activation of PG-specific T cells but did not alter T cell cytokine production.
CD80/86 expression on B cells is necessary for optimal secondary PG-specific T cell responses
It is generally accepted that naive T cells require recognition of costimulatory molecules on APCs for activation, whereas memory T cells do not require a costimulatory signal for secondary recall responses (34) . To assess whether PG-specific CD4 ϩ T cells from arthritic WT mice require recognition of costimulatory molecules on B cells, we activated CD4 ϩ T cells in the presence of B cells from WT or CD80/86 Ϫ/Ϫ mice (Fig. 7) . B cells were either naive or stimulated with LPS overnight to up-regulate costimulatory molecule expression. The proliferation of PG-specific CD4 ϩ T cells was 3-6 times higher in the presence of WT B cells activated with LPS in comparison to unstimulated WT B cells (Fig. 7) . However, B cells from CD80/86 Ϫ/Ϫ mice, regardless of whether or not they were stimulated with LPS, were significantly less effective at stimulating PG-specific T cell proliferation. These data demonstrate that PG-specific T cell recall responses require B cell expression of CD80/86 and suggest that in PGIA, chronic restimulation of the T cells may also require B cells to express CD80/86. chimeras. In contrast, B cell:CD80/86 ϩ/ϩ chimeras develop robust disease similar to that of nonchimeric WT mice. Our findings indicate that the expression of CD80/86 on B cells is essential for the development of arthritis. Because PGIA does not develop in the absence of PG-specific Abs, we assessed B cell autoantibody production. There was a similar concentration of serum IgG1 Abs specific for human and mouse PG in B cell:CD80/86 Ϫ/Ϫ chimeras, B cell:CD80/86 ϩ/ϩ chimeras, and nonchimeric WT mice. These results indicate that B cell expression of CD80/86 is not necessary for B cell Ab production, confirming a similar report under physiological conditions (27) .
We next addressed whether autoreactive T cell activation is defective in B cell:CD80/86 Ϫ/Ϫ chimeras. To address this question, we transferred T cells from the chimeras along with T cell-depleted spleens from arthritis WT mice as a source of B cells and APCs into SCID recipients. Our findings clearly show that only if the B cells express CD80/86 are the T cells able to effectively transfer arthritis. Furthermore, the CD4 ϩ T cell secondary recall response to PG is reduced in T cells recovered from the SCID recipients that were primed in the absence of CD80/86-expressing B cells. These results suggest that there is a reduction in the PGspecific effector or memory T cell pool activated in the absence of CD80/86-expressing B cells.
Our findings indicate that other APC populations, macrophages, and DCs expressing CD80/CD86 in the B cell:CD80/86 Ϫ/Ϫ chimeras activate T cells, because T-dependent PG-specific autoantibody responses are intact. Paradoxically, these T cells are not sufficient to induce arthritis. The reduction in PG-specific T cell proliferation suggests that fewer PG-specific T cells have been activated. It is possible that a substantially more robust PG-specific T cells response is required to induce arthritis than to activate B cell Ig production.
B cell activation of T cells is generally considered to be restricted to memory T cells. This is based on the dependence of B cells on help from activated CD4 T cells to become competent APCs. B cell maturation into competent APCs requires cross-linking the BCR and signals provided by CD154 on activated T cells and the CD40 receptor on B cells. Signals derived from CD154/ CD40 interaction up-regulate the expression of ICAM-1, MHC class II and CD80/86 (36 -39) . It has been suggested that memory T cells do not require recognition of CD80/86 for recall responses, indicating that B cells might function as APCs independently of CD80/86 expression (40, 41) . We demonstrate that the PG-specific T cell recall response in vitro required resting or activated B cells to express CD80/86. Thus, the block in development of arthritis in the B cell CD80/86 Ϫ/Ϫ chimeric mice is likely due to a reduction in the expansion of PG-specific T cells. This decreased activation and/or expansion of PG-specific T cells was confirmed in T cells recovered from SCID recipients where CD4 ϩ T cell proliferation is reduced in T cells initially activated in the presence of CD80/ 86-deficient B cells. Our findings are in agreement with others demonstrating that the blockade of CD28:CD80/86 interaction with CTLA4Ig inhibits secondary responses mediated by memory CD4 ϩ T cells (42) . These studies are also in accord with the clinical efficacy in RA patients treated with CTLA4Ig where disease is driven by memory T cells (43) .
In RA patients, cells infiltrating the synovium are either diffusely scattered among tissue-resident cells or organized into microstructures (44) . In a subset of RA patients, aggregates of T and B cells organize into structures resembling germinal centers found in the lymphoid follicles of secondary lymphoid organs. These synovial lesions may be important sites of T cell and B cell interactions at the site of inflammation (45) . In experiments involving the adoptive transfer of RA synovium into SCID mice, activation of T cells was dependent on the presence of B cells (46) . Our findings suggest the possibility that interference with costimulatory interaction between T cells and B cells in these synovial lesions would block T cell activation. Thus, clinical efficacy of CTLA4Ig in RA patients may be due to the distribution of these organized structures limiting T cell activation.
We previously reported that PG-specific B cells are required for the development of autoreactive T cells in PGIA. The present studies expand these findings to demonstrate that a CD80/86:CD28 costimulatory interaction between B cells and T cells is required for autoreactive T cell activation and the induction of arthritis. It has now been undoubtedly shown that B cell depletion in RA reduces disease activity (1) (2) (3) . Although autoantibodies are decreased in many individuals, autoantibody titers do not always correlate with efficacy of treatment. Our findings clearly demonstrate a critical role for B cells as APCs. Similarly, B cells are likely active participants in autoreactive T cell activation in RA. Thus, B cell presentation of Ag and expression of costimulatory molecule is essential for autoreactive T cell activation and the development of arthritis.
